Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.
Dr. Cátia Moutinho is a group Leader at the Garvan-Weizmann Centre for Cellular Genomics, at the Garvan Institute. Her team focuses on single-cell genomics development. She is a biologist by training, with a PhD in Biomedicine and a master’s in clinical Trials and Medical Affairs. She has an extensive experience in the wet-lab, with a strong background in single-cell technology, as well as cancer genetics and epigenetics. She has more than 45 scientific publications in peer-reviewed journals including original papers and a book chapter. After starting her professional career in Oporto, Portugal, and working in Madrid and Barcelona for more than 10 years, she decided to embark on a new journey in Sydney, Australia, where she is currently residing.
Dr. Wei Vivian Li is an Assistant Professor in the Department of Biostatistics and Epidemiology at the Rutgers University, and an associate member of the Rutgers Cancer Institute of New Jersey. Before joining Rutgers, she obtained her Ph.D. degree in Statistics from the University of California, Los Angeles. Vivian's lab is interested in statistical modeling and algorithm development, as well as their applications to high-throughput sequencing data in bioinformatics and clinical research. Major research topics of her lab include statistical modeling and experimental design of bulk and single-cell genomic data, alternative RNA splicing and polydenylation, and gene regulatory networks.
Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA.
Grace Zhao is a co-founder of Avida Biomed, a biotech start-up specializing in genomic technology innovation for molecular diagnostics. At Avida, Grace co-invented Point-n-Seq, a new platform technology to advance liquid biopsy for early detection of cancer and other diseases. Utilizing the ultra-efficient, hybridization-based pre-amplification enrichment of target molecules from nanogram level cell free DNA (cfDNA), Point-n-Seq enables the first targeted mutation and methylation cfDNA dual analysis solution on market. Grace is currently the head of clinical research defining and executing company-wide clinical research strategy.Before Avida, Grace co-founded AccuraGen, which focused on accurate genomic solutions for cfDNA based liquid biopsy. AccuraGen has developed a series of products for cancer molecular diagnostics for the China market. As the director of research, Grace co-invented the core technology and managed a cross-continental research team, as well as the company’s numerous clinical collaborations.Grace received her PhD from UCSD, followed by a postdoctoral training at Stanford School of Medicine.
Bhagya is the Global Commercial Product Manager Beckman Coulter Life Sciences automation. Trained as a Molecular Biologists she has 15 years of experience in genomics and sequencing technologies. She received her doctoral degree from the department of Biology at Purdue University. Her thesis research focused on evolutionary genomics of human parasites and their hosts. As a monogrammed medicine fellow at Indiana University School of Medicine she worked with a team of multidisciplinary researchers to identify personalized drug combination treatments for cancer. Bhagya holds a Master of Business Administration from Texas A&M University of Commerce.
Dr. Mane completed his PhD from The University of Bombay and postdoctoral studies from The Johns Hopkins University School of Medicine. He is the professor of genetics and the executive director of Yale Center for Genome Analysis, one of the most scientifically productive and accomplished Genome Centers. He has authored more than 175 articles papers in reputed journals and has served as an ad hock reviewer of several journals. He is also one of the principal investigators of Yale Centers of Mendelian Genomics, funded via a total of $22 million grant from NIH
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.
Paul Keown is Professor of Medicine and Director of Immune Sciences at the University of British Columbia and Lead of the Genome Canada Transplant Consortium. He received his MD and DSc degrees in the UK with post-doctoral research in immunology and clinical medicine in Europe and Canada.
Karen Sherwood is Lead Genome Scientist and Director of Scientific Programs for the Genome Canada Transplant Consortium. She received her PhD degree in Edinburgh with post-doctoral research in gene sequencing and neuropathology in the UK and Canada.
Miten is an Assistant Research Scientist at the University of California Santa Cruz. He did his PhD in Biomolecular Engineering and Bioinformatics at UC Santa Cruz in the nanopore group. His prior work and research interests include developing biological methods and software for: 1) analyzing genomics data; 2) long read sequencing of DNA and RNA; 3) resolving homopolymers and base modifications; 4) the nanopore MinION and PromethION sequencing platforms; and 5) sequencing and analysis of different classes of RNA (mRNA, rRNA, tRNA, non-coding RNA). His long term interests include combining sequence and structure information from DNA (genomics), RNA (coding and non-coding), and proteins, to better understand genome organization and function.
Jonathan Preall is the Director of Cold Spring Harbor Laboratory's Single Cell Biology Shared Resource and the Head of Genomics Technology Development. His career has spanned academia and industry with a focus on genetics and genomics applications. His current research focuses on technology development in the field of single cell genomics and the integration of large-scale datasets with recently generated single cell atlases.
